Current Therapeutic Options for Huntington's Disease: Good Clinical Practice Versus Evidence-Based Approaches?

被引:47
作者
Killoran, Annie [1 ]
Biglan, Kevin M. [2 ]
机构
[1] W Virginia Univ, Morgantown, WV 26501 USA
[2] Univ Rochester, Rochester, NY USA
关键词
Huntington's disease; evidence-based medicine; expert opinion; treatment; EVIDENCE-BASED MEDICINE; DOUBLE-BLIND TRIAL; PHARMACOLOGICAL-TREATMENT; ANTIPSYCHOTIC MEDICATION; INVOLUNTARY MOVEMENTS; SYMPTOMATIC TREATMENT; INDUCED PARKINSONISM; FUNCTIONAL DECLINE; WESTPHAL VARIANT; DOSE OLANZAPINE;
D O I
10.1002/mds.26014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Therapeutic decision-making in Huntington's disease (HD) is often guided by clinical experience, because of the limited empirical evidence available. The only medication for HD that has met the regulatory hurdle for approval is tetrabenazine, indicated for the treatment of chorea. However, its use has limitations, and in the setting of specific contraindications or comorbidities the treatment of choice for chorea is still the multipurpose antipsychotics. For the management of psychiatric disturbances, selective serotonin reuptake inhibitors (SSRIs) and mood stabilizers are often used, although empirical evidence is lacking. Finally, no known effective treatment is available for cognitive dysfunction in HD. We discuss the limited evidence available and current expert opinion on medical treatment of the dominant motor, psychiatric, and cognitive features of HD. This follows a brief introduction on the general principles of HD management and on evidence-based medicine in relation to clinical practice. (C) 2014 International Parkinson and Movement Disorder Society
引用
收藏
页码:1404 / 1413
页数:10
相关论文
共 173 条
[11]   Earliest functional declines in Huntington disease [J].
Beglinger, Leigh J. ;
O'Rourke, Justin J. F. ;
Wang, Chiachi ;
Langbehn, Douglas R. ;
Duff, Kevin ;
Paulsen, Jane S. .
PSYCHIATRY RESEARCH, 2010, 178 (02) :414-418
[12]   Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease [J].
Beglinger, Leigh J. ;
Adams, Williams H. ;
Paulson, Henry ;
Fiedorowicz, Jess G. ;
Langbehn, Douglas R. ;
Duff, Kevin ;
Leserman, Anne ;
Paulsen, Jane S. .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 29 (05) :484-487
[13]   Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders [J].
Bhandary, AN ;
Masand, PS .
PSYCHOSOMATICS, 1997, 38 (04) :389-391
[14]   The effects of modafinil on mood and cognition in Huntington's disease [J].
Blackwell, Andrew D. ;
Paterson, Nicole S. ;
Barker, Roger A. ;
Robbins, Trevor W. ;
Sahakian, Barbara J. .
PSYCHOPHARMACOLOGY, 2008, 199 (01) :29-36
[15]   Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease [J].
Blass, DM ;
Steinberg, M ;
Leroi, I ;
Lyketsos, CG .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (12) :1966-1972
[16]   Ziprasidone in Huntington's disease: the first case reports [J].
Bonelli, RM ;
Mayr, BM ;
Niederwieser, G ;
Reisecker, F ;
Kapfhammer, HP .
JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (04) :459-460
[17]   Zotepine in Huntington's disease [J].
Bonelli, RM ;
Niederwieser, G ;
Lahousen, T ;
Hofmann, P .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2003, 18 (03) :227-229
[18]   Mirtazapine in suicidal Huntington's disease [J].
Bonelli, RM .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (03) :452-452
[19]   Quetiapine in Huntington's disease: a first case report [J].
Bonelli, RM ;
Niederwieser, G .
JOURNAL OF NEUROLOGY, 2002, 249 (08) :1114-1115
[20]   Olanzapine for Huntington's disease: An open label study [J].
Bonelli, RM ;
Mahnert, FA ;
Niederwieser, G .
CLINICAL NEUROPHARMACOLOGY, 2002, 25 (05) :263-265